Ali Iftikhar completed his MS at the Cancer Therapeutics Laboratory, Lahore University of Management Sciences (LUMS). His research involved identifying a novel MST2 inhibitor with implications in estrogen receptor-positive breast cancer. He also developed an in-house compound library and contributed to various projects focused on microtubules, FLT3, ABL1, and high-throughput screening. He is currently a Research Associate at the Cancer Therapeutics Laboratory.
